How should enoxaparin be dosed in a 60‑kg patient with a creatinine clearance of 70 mL/min?

Enoxaparin Dosing for 60-kg Patient with CrCl 70 mL/min

For a 60-kg patient with a creatinine clearance of 70 mL/min, use standard weight-based enoxaparin dosing without renal adjustment—the dose depends entirely on the clinical indication.

Clinical Context Determines Dose

With a CrCl of 70 mL/min, this patient has normal renal function and requires no dose reduction. Renal dose adjustments for enoxaparin are only necessary when CrCl falls below 30 mL/min 1, 2.

For Acute Coronary Syndromes (ACS):

• Initial therapy: 1 mg/kg subcutaneous every 12 hours = 60 mg every 12 hours 1
• With fibrinolytic therapy (age <75 years): 30 mg IV bolus, then 1 mg/kg subcutaneous every 12 hours (maximum 100 mg for first 2 doses) = 30 mg IV bolus, then 60 mg subcutaneous every 12 hours 1
• To support PCI: Dosing depends on timing of last subcutaneous dose 1

For VTE Prophylaxis:

• Hospitalized medical patients: 40 mg once daily 3
• Surgical patients: 40 mg once daily (starting 2-4 hours preoperatively or 10-12 hours preoperatively) 3
• High-risk outpatients: 40 mg once daily 3

For VTE Treatment:

• Initial treatment: 1 mg/kg every 12 hours = 60 mg every 12 hours OR 1.5 mg/kg once daily = 90 mg once daily 3
• Long-term treatment: 1.5 mg/kg once daily or 1 mg/kg every 12 hours 3

Key Pharmacokinetic Considerations

Renal function is the primary determinant of enoxaparin clearance 4, 5. At CrCl 70 mL/min, enoxaparin clearance is only mildly reduced compared to normal renal function. Research shows:

• Enoxaparin clearance correlates linearly with CrCl (R = 0.85, p < 0.001) 6
• The fraction of drug excreted unchanged is approximately 71% 5
• Accumulation and increased bleeding risk occur primarily when CrCl <30 mL/min 6

For this patient with CrCl 70 mL/min, standard dosing is appropriate without adjustment 6, 5.

Common Pitfalls to Avoid

1. Do not empirically reduce the dose based on mild renal impairment—this increases risk of inadequate anticoagulation and thrombotic events 5

2. Do not switch between enoxaparin and UFH once therapy is initiated—this increases bleeding risk 1, 2

3. Weight-based dosing is critical—use actual body weight up to 144 kg for enoxaparin 6

4. Gender matters for pharmacokinetics—women have lower clearance and longer half-lives (9.2 vs 6.4 hours in men), but standard dosing still applies 4

5. Monitor for drug accumulation only if renal function deteriorates to CrCl <30 mL/min during therapy 6